{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.42","pValueComment":"Two-sided","statisticalMethod":"Chi-squared"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"303"}],"units":"Participants"}],"description":"AEs are graded by using CTCAE 3.0. The difference between the two randomized arms in the percentage of patients with grade 3 or higher toxicities reported as possibly/probably/definitely related to protocol treatment will be tested using a chi square test.","groups":[{"description":"Temozolomide post-randomization,Radiation therapy post-randomization, placebo","id":"OG000","title":"Randomized Arm 1: TMZ+RT + Placebo"},{"description":"Temozolomide post-randomization, radiation therapy post-randomization, bevacizumab","id":"OG001","title":"Randomized Arm 2: TMZ+RT + Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Eligible randomized patients with adverse event data who started study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 30 days","title":"Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0","type":"SECONDARY","unitOfMeasure":"participants"}